---
title: "DSG3"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "# Gene: DSG3"
tags: ['DSG3', 'Desmoglein3', 'Pemphigus', 'Autoimmune', 'Treatment', 'Rituximab', 'Mutation', 'Prognosis']
---

# Gene: DSG3

## Genetic Position
The DSG3 gene is located on the short arm of chromosome 18, at position 12.1 (18p12.1).

## Pathology
The DSG3 gene encodes desmoglein-3, a calcium binding transmembrane glycoprotein that is a member of the desmosomal cadherin family. Mutations in this gene have been associated with various types of pemphigus, an autoimmune disorder that affects the skin and mucous membranes.

## Function
Desmoglein-3 is a component of desmosomes, which are intercellular junctions that provide mechanical strength to tissues that experience high levels of mechanical stress. In skin, desmoglein-3 is responsible for maintaining the integrity of the epidermis by mediating the adhesion between keratinocytes. 

## External IDs and Aliases
- HGNC:2912
- NCBI Entrez: 1830
- Ensembl: ENSG00000141568
- OMIM: 604406
- UniProtKB/Swiss-Prot: Q14574
- Aliases: Pemphigus vulgaris antigen, CDHF15, pemphigus foliaceus antigen

## AA mutation list and mutation type with dbSNP ID
- c.2557C>T (p.Arg853Ter) - rs104893962
- c.2540delG (p.Val847Serfs*35) - rs104893963
- c.452G>A (p.Ala151Thr) - rs61754334

## Somatic SNVs/InDels with dbSNP ID
- c.1135G>A (p.Gly379Ser) - rs794728774
- c.1739A>G (p.Gln580Arg) - rs797044538

## Related Disease
Mutations in DSG3 have been linked to several types of pemphigus, including pemphigus vulgaris (PV) and pemphigus foliaceus (PF). In these disorders, the immune system mistakenly attacks desmoglein-3, resulting in the disintegration of desmosomes and the separation of keratinocytes.

## Treatment and Prognosis
Treatment for pemphigus typically involves systemic corticosteroids and immunosuppressive agents to reduce inflammation and prevent antibody production. Prognosis depends on the severity of the disease and the patient's response to treatment. In severe cases, pemphigus can be life-threatening.

## Drug Response
Various drugs have been used in the treatment of pemphigus. In recent years, rituximab, an anti-CD20 monoclonal antibody, has emerged as a promising therapy for pemphigus and has shown efficacy in several clinical studies.

## Related Papers
- Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (1999) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 341(22): 1587-1590. doi: 10.1056/NEJM199911253412203
- Amagai M, Klaus-Kovtun V, Stanley JR (1991) Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67(5): 869-877. doi: 10.1016/0092-8674(91)90360-6
- Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR (2000) Homozygous deletion of the desmocollin 3 gene in a case of pemphigus vulgaris. Br J Dermatol 143(2): 357-362. doi: 10.1046/j.1365-2133.2000.03691.x

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**